Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs – Fierce Healthcare
Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs Fierce Healthcare
Oral Semaglutide: Trends Suggest Potential Kidney Benefits
While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn’t match the effects seen with the injectable formulation in the FLOW trial, the observed trends suggest improvements. Medscape Medical News
Men Are Reporting ‘Ozempic Penis’ – But Experts Say It’s Not What They Think
Man wearing a belt Recently, Redditors in an Ozempic forum shared an unexpected perceived side-effect of taking the semaglutide jab. “Increased size, anyone else notice?” the site user wrote. In the comments, multiple site users confirmed they’d also seen change, which some have called “Ozempic penis.” They’re not alone. Diabetes.co.uk suggested that the 10% increase […]
Uncovering unexpected impacts of popular GLP-1 diabetes drugs
GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for vigilance regarding new health risks.
Bariatric Surgery Beats GLP-1 RAs for Sustained Weight Loss
Bariatric surgery is associated with a significantly greater long-term weight loss than treatment with GLP-1 receptor agonists, a new head-to-head real-world study finds. Medscape Medical News
Kerry Group gauges probiotic potential in the age of GLP-1
As GLP-1 weight loss drugs become more common, managing side effects has emerged as key to adherence. A Kerry Group consumer perception study suggests its BC30 Probiotic may help reduce digestive discomfort linked to these medications.
STAT+: Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease. Lilly will acquire Verve for $10.50 per share, a premium of nearly 70% to the biotech’s share price at Monday’s close. The deal also includes an additional payment of $3 per share contingent on the first patient […]
Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The collaboration is valued at over $650 million, with the majority of this sum tied to the achievement of specific development and commercialization […]
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not paying a nominal maintenance fee years before it became a blockbuster drug for fighting diabetes and obesity, Science reported. Novo Nordisk generates billions of dollars in revenue on the drug in Canada, but patent […]
STAT+: China, where obesity levels are low, becomes hotbed for weight loss drug trials
China has one of the lowest rates of obesity in the developed world. So why has it emerged as one of the top locations for testing the scores of new weight loss drugs cropping up every month? According to a report from clinical research organization Novotech, China is the second-most-popular country for obesity trials in […]